Search

Displaying results 3201 - 3210 of 10000 in total
  1. Drug

    Tetracosactide

    go.drugbank.com/drugs/DB01284
    ApprovedInvestigational

    The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. … Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone.

    Products: SYNACTHEN DEPOT 1 MG AMPUL, 1 ADET
  2. Drug

    LGD-1550

    go.drugbank.com/drugs/DB05785
    Experimental

    LGD-1550 is an orally-active synthetic aromatic retinoic acid agent with potential antineoplastic and chemopreventive activities.

  3. Drug

    Lecanemab

    go.drugbank.com/drugs/DB14580
    ApprovedInvestigational

    [L44537] Lecanemab works to reduce Aβ plaques and prevent Aβ deposition in the brain [A253947,A253952] with high selectivity to Aβ protofibrils. … Lecanemab is a recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta (Aβ), which are implicated in the pathophysiology

  4. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. … The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

  5. Drug

    Ceftibuten

    go.drugbank.com/drugs/DB01415
    ApprovedInvestigational

    Ceftibuten is a third-generation cephalosporin antibiotic that is orally-administered. … It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

    Mixtures: BUCEF PLUS 180/62.5 MG TOZ ICEREN SASE, 20 ADET, BUCEF PLUS 90/62.5 MG TOZ ICEREN SASE, 20 ADETProducts: BUCEF 180 MG SASE, 20 ADET, BUCEF 90 MG SASE, 20 ADET
  6. Drug

    Gefitinib

    go.drugbank.com/drugs/DB00317
    ApprovedInvestigational

    Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. … Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.

    Products: İRESSA 250 MG FİLM KAPLI TABLET, 30 ADET, GEFIRA 250 MG FİLM KAPLI TABLET, 30 ADET
  7. Drug

    Emicizumab

    go.drugbank.com/drugs/DB13923
    ApprovedInvestigational

    Emicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co. … Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X.

    Products: ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, ENJEKSİYONLUK ÇÖZELTİ, 1 ADET
  8. Drug

    Buspirone

    go.drugbank.com/drugs/DB00490
    ApprovedInvestigational

    Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. … It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin reuptake inhibitors (SSRIs) is deemed clinically inadequate or inappropriate.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: NOPIRON 5 MG TABLET, 25 ADET, NOPIRON 5 MG TABLET, 50 ADET
  9. Drug

    Anecortave acetate

    go.drugbank.com/drugs/DB05288
    Investigational

    Anecortave acetate (Retaane) is an analog of cortisol acetate; among the modifications to the steroid are the removal of the 11ß hydroxyl OH group and an addition of a 21-acetate group. … As a result of these modifications, anecortave acetate lacks the typical antiinflammatory and immunosuppressive properties of glucocorticoids.Alcon Inc. is developing and marketing Retaane.

  10. Drug

    Entrectinib

    go.drugbank.com/drugs/DB11986
    ApprovedInvestigational

    [L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. … This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ROZLYTREK 200 MG SERT KAPSÜL, 90 ADET, ROZLYTREK 100 MG SERT KAPSÜL , 30 ADET